I am a Senior Research Fellow in the Section of Immunology of Infection. I obtained my BSc in Chemistry and my PhD in Biochemistry, working on the role of adenosine and adenosine deaminase in immunodeficiencies, at the University of Barcelona, Spain. I then joined the group of Prof. John P. Moore at the Weill Medical College of Cornell University, New York, USA. As a Postdoctoral Fellow, I had the opportunity to make my first steps in the field of HIV working in the areas of neutralizing antibodies and CCR5 co-receptor.
My primary research interests are mucosal infection and inflammation. Using ex vivo tissue models, I study mucosal responses during transmission of HIV/SIV, HCV, and Zika virus. These primary tissue models also allow pre-clinical evaluation of prevention strategies, including pre-exposure prophylaxis and vaccine candidates. I have recently expanded the potential of the ex vivo tissue models to investigate inflammation and associated pathologies such as Inflammatory Bowel Disease.
During the last 10 years, I have been funded as PI or co-investigator by amfAR, HVTN-CHAVI, EU Commission FP7 Health 2012 Innovation, EDCTP, NIH, Canadian Institute for Health Research, Manitoba Health Research, Henry Jackson Foundation, Pfizer, Gilead, Merck and CHAIN Biotechnology.
et al., 2021, Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial, Hiv Research & Clinical Practice, Vol:22, ISSN:2578-7489, Pages:151-159
et al., 2021, The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate, Aids, Vol:35, ISSN:0269-9370, Pages:1907-1917
et al., 2021, Peptide Amphiphilic-Based Supramolecular Structures with Anti-HIV-1 Activity, Bioconjugate Chemistry, Vol:32, ISSN:1043-1802, Pages:1999-2013
et al., 2021, Optimized protocol for a quantitative SARS-CoV-2 duplex RT-qPCR assay with internal human sample sufficiency control., Journal of Virological Methods, Vol:294, ISSN:0166-0934, Pages:1-7
et al., 2021, Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP), Journal of Antimicrobial Chemotherapy, Vol:76, ISSN:0305-7453, Pages:2129-2136